First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases

Aldo Borroto, Diana Reyes-Garau, M. Ángeles Jiménez, Esther Carrasco, Beatriz Moreno, Sara Martinez‐Pasamar, José R. Cortés, Almudena Perona, David Abia, Soledad Blanco,

Science Translational Medicine · 2016 · 59 citations · 34 references

Concepts

Abstract

(median inhibitory concentration) ~1 nM. By modulating TCR signaling, the inhibitor prevented the development of psoriasis and asthma and, furthermore, exerted a long-lasting therapeutic effect in a model of autoimmune encephalomyelitis. However, it did not prevent the generation of a protective memory response against a mouse pathogen, suggesting that the compound might not exert its effects through immunosuppression. These results suggest that inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases.

References

34